全文获取类型
收费全文 | 1439篇 |
免费 | 100篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 24篇 |
妇产科学 | 7篇 |
基础医学 | 205篇 |
口腔科学 | 24篇 |
临床医学 | 139篇 |
内科学 | 343篇 |
皮肤病学 | 9篇 |
神经病学 | 104篇 |
特种医学 | 44篇 |
外科学 | 165篇 |
综合类 | 54篇 |
预防医学 | 170篇 |
眼科学 | 12篇 |
药学 | 143篇 |
中国医学 | 1篇 |
肿瘤学 | 85篇 |
出版年
2023年 | 26篇 |
2022年 | 37篇 |
2021年 | 93篇 |
2020年 | 59篇 |
2019年 | 72篇 |
2018年 | 75篇 |
2017年 | 40篇 |
2016年 | 47篇 |
2015年 | 43篇 |
2014年 | 52篇 |
2013年 | 68篇 |
2012年 | 77篇 |
2011年 | 111篇 |
2010年 | 55篇 |
2009年 | 40篇 |
2008年 | 78篇 |
2007年 | 80篇 |
2006年 | 92篇 |
2005年 | 64篇 |
2004年 | 63篇 |
2003年 | 77篇 |
2002年 | 48篇 |
2001年 | 28篇 |
2000年 | 17篇 |
1999年 | 21篇 |
1998年 | 22篇 |
1997年 | 7篇 |
1996年 | 8篇 |
1995年 | 5篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 3篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 2篇 |
1982年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1968年 | 1篇 |
1965年 | 1篇 |
1963年 | 1篇 |
1961年 | 1篇 |
1960年 | 1篇 |
1959年 | 1篇 |
1957年 | 1篇 |
1928年 | 1篇 |
1926年 | 1篇 |
排序方式: 共有1548条查询结果,搜索用时 15 毫秒
71.
Maria Chatzopoulou Katrina S. Madden Liam J. Bromhead Christopher Greaves Thomas J. Cogswell Solange Da Silva Pinto SbastienR. G. Galan Irene Georgiou Matthew S. Kennedy Alice Kennett Geraint Apps Angela J. Russell Graham M. Wynne 《ACS medicinal chemistry letters》2022,13(2):262
Palladium-catalyzed reactions are among the most commonly used procedures in organic synthesis. The products have a range of uses, including as intermediates in total synthesis and as screening compounds for drug discovery or agrochemical projects. Despite the known and potentially deleterious effects of low-level metal impurities in biological assays, the quantification of metal remaining in reaction products to verify the effective removal of the transition element is rarely reported. Using palladium as an exemplar, we describe a pilot study that for the first time quantifies residual metal levels in reaction products following increasingly rigorous purification protocols. Our results demonstrate that significant levels of residual palladium can remain in isolated reaction products following chromatographic purification, and only by using a subsequent metal scavenging step are they reliably reduced to a low level. Finally, we provide a set of simple guidelines that should minimize the potential for issues associated with residual palladium in reaction products. 相似文献
72.
73.
74.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
75.
76.
Brenda Happell RN Cert Psych Nurs BA DipEd MEd PhD FACMHN Shifra Waks BA MIHP B Int Global Stud Aine Horgan PhD MSc BNS PGCert T&L RPN Sonya Greaney DipSPH PG Cert Peer Support Fionnuala Manning John Goodwin MA PGDip Bsc BA ALCM DipMgmt RPN Julia Bocking BPhil B Soc & Comm Stud Brett Scholz BHSci PhD Elisabeth Hals MA Arild Granerud PhD Rory Doody B.Soc.Sc. Chris Platania-Phung BA PhD Martha Griffin H. Dip in Community Youth Work Siobhan Russell BSc RPN PhD Liam MacGabhann BSc MSc DrNursSci Jarmo Pulli Annaliina Vatula BA Graeme Browne RN MHN PhD FACMHN Kornelis Jan van der Vaart BN MSci Jerry Allon Einar Bjornsson Heikki Ellilä RN MNSc PhD Mari Lahti MNSc PhD Pall Biering PhD 《Perspectives in psychiatric care》2020,56(4):811-819
77.
Lin Alexander J. Kane Liam T. Molitoris Jason K. Smith Deborah R. Dahiya Sonika Badiyan Shahed N. Wang Tony J. C. Kruser Tim J. Huang Jiayi 《Journal of neuro-oncology》2020,146(1):121-130
Journal of Neuro-Oncology - Practice patterns vary for adjuvant treatment of 1p/19q-codeleted oligodendroglioma patients. This study evaluates the outcomes of adjuvant (aRT) versus salvage... 相似文献
78.
Ioana Agache Cezmi A. Akdis Mubeccel Akdis Knut Brockow Tomas Chivato Stefano del Giacco Thomas Eiwegger Kilian Eyerich Ana Giménez-Arnau Jan Gutermuth Emma Guttman-Yassky Marcus Maurer Graham Ogg Peck Y. Ong Liam O’Mahony Jürgen Schwarze Amena Warner Thomas Werfel Oscar Palomares Marek Jutel 《Allergy》2021,76(4):988-1009
Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of atopic dermatitis, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based), its cost-effectiveness and long-term safety. The EAACI Guidelines on the use of dupilumab in atopic dermatitis follow the GRADE approach in formulating recommendations for each outcome and age group. In addition, future approaches and research priorities are discussed. 相似文献
79.
Repeatability and sensitivity of
measurements in patients with head and neck squamous cell carcinoma at 3T
下载免费PDF全文
![点击此处可从《Journal of magnetic resonance imaging : JMRI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Rafal Panek PhD Liam Welsh PhD Alex Dunlop PhD Kee H. Wong MSc Angela M. Riddell MD Dow‐Mu Koh MD Maria A. Schmidt PhD Simon Doran PhD Dualta Mcquaid PhD Georgina Hopkinson PgDip Cheryl Richardson DCR Christopher M. Nutting PhD Shreerang A. Bhide PhD Kevin J. Harrington PhD Simon P. Robinson PhD Kate L. Newbold MD Martin O. Leach PhD 《Journal of magnetic resonance imaging : JMRI》2016,44(1):72-80
80.
Heterotopic ossification (HO) is the formation of pathological bone in ectopic sites and it can have serious consequences for functional outcomes. For many years, its main clinical relevance was as a rare complication of elective joint arthroplasty or CNS injury and a number of prophylaxes were developed to mitigate against it in these settings. As a consequence of changes in patterns of wounding and survival in conflicts since the turn of the century, post‐traumatic HO has become much more common and case severity has increased. It represents one of the main barriers to rehabilitation in a large cohort of combat‐injured patients. However, extant prophylaxes have not been shown to be effective or appropriate in this patient cohort. In addition, the lack of reliable early detection or means of predicting which patients will develop HO is another barrier to effective prevention. This review examines the current state of understanding of post‐traumatic HO including the historical context, epidemiology, pathophysiology, clinical issues, currently prophylaxis and detection, management, and potential future approaches. Our aims are to highlight the current lack of effective means of early detection and prevention of HO after major trauma and to stimulate research into novel solutions to this challenging problem. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1061–1068, 2018. 相似文献